NEWS
OKLAHOMA CITY – Min Li, Ph.D., George Lynn Cross Research Professor of Medicine, Surgery and Cell Biology at the University of Oklahoma College of Medicine and Associate Director for Global Oncology at OU Health Stephenson Cancer Center, has been named president of the International Association of Pancreatology (IAP).
The IAP, established in 1985, works with national and regional societies to promote pancreatology throughout the world and to find new treatments for pancreatic disorders. The organization has more than 3,500 members, both basic scientists and clinical investigators, from 32 countries.
Li has dedicated his career to understanding the biology of pancreatic cancer and finding new answers for its treatment. He is also known as a scholar of cancer cachexia, a muscle-wasting condition that affects the majority of patients diagnosed with pancreatic cancer.
He said he looks forward to working with colleagues to advance research, education and innovation in pancreatology.
“It is a privilege to serve as president of the IAP,” Li said. “This role provides the opportunity to bring together experts from around the world to address the many challenges of pancreatic diseases. By strengthening international partnerships and sharing new discoveries, we can help shape the future of pancreatology for patients everywhere.”
Li has been with the OU College of Medicine since 2014. He has been awarded a significant amount of federal funding for his research and has published high-impact articles for several consecutive years in leading journals, including Cell, Cancer Cell, Proceedings of the National Academy of Sciences (PNAS), EMBO Molecular Medicine, Gastroenterology, Cancer Research, and Clinical Cancer Research.
“We are building a world-class basic science and translational research program in pancreatic cancer at OU,” he said. “This is an exciting time for pancreatic cancer research.”
Li is past president of the American Pancreatic Association, and he is editor-in-chief of the journal Cancer Letters. He holds the Virginia Kerley Cade Endowed Chair in Cancer Treatment at the OU College of Medicine, and he is Vice Chair for Research in the Department of Medicine. He also serves as Assistant Dean for International Research Collaboration in the College of Medicine.
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state’s flagship university, OU serves the educational, cultural, economic and healthcare needs of the state, region and nation. In Oklahoma City, the OU Health Campus is one of the nation’s few academic health centers with seven health profession colleges located on the same campus. The OU Health Campus serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about the OU Health Campus, visit www.ouhsc.edu.
Wei Yue, Ph.D., a professor of pharmaceutical sciences in the OU College of Pharmacy, has received a $1.9 million National Institutes of Health award to uncover new ways to predict when multiple medications taken together could cause dangerous side effects.
People with type 2 diabetes were much more likely to achieve remission after weight-loss surgery than after intensive medical and lifestyle management, according to a long-term study. Researchers also identified patient characteristics linked to remission and to the likelihood of diabetes returning.
The University of Oklahoma College of Law has named Oklahoma Supreme Court Justice James R. Winchester as the 2026 recipient of the Eugene Kuntz Award. The annual award recognizes professionals who have made significant contributions to oil, gas and natural resources law.
